Search Results - "BIGAUD, Marc"

Refine Results
  1. 1

    Second generation S1P pathway modulators: Research strategies and clinical developments by Bigaud, Marc, Guerini, Danilo, Billich, Andreas, Bassilana, Frederic, Brinkmann, Volker

    Published in Biochimica et biophysica acta (01-05-2014)
    “…Multiple Sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system (CNS) through demyelination and neurodegeneration. Until…”
    Get full text
    Journal Article
  2. 2

    Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis by Weier, Alicia, Enders, Michael, Kirchner, Philipp, Ekici, Arif, Bigaud, Marc, Kapitza, Christopher, Wörl, Jürgen, Kuerten, Stefanie

    “…Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS). Although immune modulation and suppression are effective during…”
    Get full text
    Journal Article
  3. 3

    Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration by Torres, Julia Baguña, Roodselaar, Jay, Sealey, Megan, Ziehn, Marina, Bigaud, Marc, Kneuer, Rainer, Leppert, David, Weckbecker, Gisbert, Cornelissen, Bart, Anthony, Daniel C

    Published in Frontiers in immunology (28-07-2022)
    “…Approval of B-cell-depleting therapies signifies an important advance in the treatment of multiple sclerosis (MS). However, it is unclear whether the…”
    Get full text
    Journal Article
  4. 4

    Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights by Bigaud, Marc, Rudolph, Bettina, Briard, Emmanuelle, Beerli, Christian, Hofmann, Andreas, Hermes, Erwin, Muellershausen, Florian, Schubart, Anna, Gardin, Anne

    “…Background Siponimod (BAF312), a selective S1P1/S1P5 agonist, reduces disability progression in secondary progressive MS. Recent observations suggest it could…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7
  8. 8

    Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod? by Bigaud, Marc, Ramseier, Pamela, Tisserand, Sarah, Lang, Meike, Urban, Beatrice, Beerli, Christian, Karlsson, Göril

    Published in Neurology and therapy (01-08-2023)
    “…Introduction Siponimod, a potent and selective sphingosine-1-phosphate (S1P 1,5 ) agonist, is the only therapeutic agent that has shown efficacy against…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Reduced cardiac side-effect potential by introduction of polar groups: Discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo by Thoma, Gebhard, Beerli, Christian, Bigaud, Marc, Bruns, Christian, Cooke, Nigel G., Streiff, Markus B., Zerwes, Hans-Guenter

    Published in Bioorganic & medicinal chemistry (15-03-2008)
    “…Introduction of polar groups in a series of potent CCR5 antagonists which are very likely to adversely affect the conduction system in the heart led to the…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19

    A simple method to optimize peripheral blood mononuclear cell preparation from cynomolgus monkeys and improve mixed lymphocyte reactions by Bigaud, Marc, Maurer, Claudine, Vedrine, Corrine, Puissant, Bénédicte, Blancher, Antoine

    “…Introduction: The standard Ficoll–Hypaque method used to isolate peripheral blood mononuclear cells (PBMC) gives very variable results when used with…”
    Get full text
    Journal Article
  20. 20